Loading data for BCAB — first visit, this takes a few seconds.
BioAtla, Inc. (BCAB)
NasdaqCM: BCAB
· 即時價格 · USD
1.18
-0.05 (-4.07%)
收盤價： Sep 09, 2026, 3:59 PM
股價、關鍵數字和最新消息，都在這一頁。
BioAtla, Inc.（BCAB）股價、分析與資料
-4.07% (1D)
| 買價 | 1.18 |
| 市值 | 2.05M |
| 營收 (ttm) | 8.5M |
| 淨利（ttm） | -31.5M |
| 0.70 | |
| -24.47 | |
| n/a | |
| -0.92 | |
| P/B (ttm) | -0.06 |
| P/S (ttm) | 0.24 |
| 財報日期 | Nov 12, 2026 |
| 賣價 | 1.3 |
| 成交量 | 172 |
| 20 日平均成交量 | 77,059 |
| 開盤價 | 1.25 |
| 前收盤價 | 1.23 |
| 當日區間 | 1.18 - 1.25 |
| 52 週範圍 | 1.07 - 71.50 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 BCAB
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to trea...
完整的公司簡介財報驚奇
BioAtla 已於 Nov 13, 2025 公布季度財報：
- 營收為 $6.5M 低於預期 $0, 年增 Infinity% 成長.
- 每股盈餘為 -13.5 超出預期 1.33, 年增 -22.73% 下滑.
